Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher McGuigan

Showing results (81-90 of 152) with videos related to

Pageof 16
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 13, 2018
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosisNuala McNicholas, Andrew Lockhart, Siew M Yap, et al.
Journal of Medicinal Chemistry|September 7, 2011
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleosideChristopher McGuigan, Paola Murziani, Magdalena Slusarczyk, et al.
European Journal of Medicinal Chemistry|May 1, 2016
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancerMarcella Bassetto, Salvatore Ferla, Fabrizio Pertusati, et al.
Medchemcomm|August 16, 2018
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agentsMarcella Bassetto, Salvatore Ferla, Gilda Giancotti, et al.
Biochemical Pharmacology|June 11, 2011
The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymesJohan Vande Voorde, Sandra Liekens, Christopher McGuigan, et al.
European Journal of Medicinal Chemistry|July 10, 2019
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF<sub>5</sub>) and pentafluoroethyl (C<sub>2</sub>F<sub>5</sub>) substituents: Improved antiproliferative agents against prostate cancerFabrizio Pertusati, Salvatore Ferla, Marcella Bassetto, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activityAnnette Angell, Christopher McGuigan, Luis Garcia Sevillano, et al.
Multiple Sclerosis and Related Disorders|September 10, 2021
Vaccine hesitancy among people with multiple sclerosisSiew Mei Yap, Mahmood Al Hinai, Maria Gaughan, et al.
Journal of Medicinal Chemistry|August 4, 2009
The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibitionMarco Derudas, Davide Carta, Andrea Brancale, et al.
Bioorganic & Medicinal Chemistry|June 24, 2011
Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTidesMaurizio Quintiliani, Leentje Persoons, Nicola Solaroli, et al.
Pageof 16

Showing results (81-90 of 152) with videos related to

Sort By:
Pageof 16
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 13, 2018
New versus old: Implications of evolving diagnostic criteria for relapsing-remitting multiple sclerosisNuala McNicholas, Andrew Lockhart, Siew M Yap, et al.
Journal of Medicinal Chemistry|September 7, 2011
Phosphoramidate ProTides of the anticancer agent FUDR successfully deliver the preformed bioactive monophosphate in cells and confer advantage over the parent nucleosideChristopher McGuigan, Paola Murziani, Magdalena Slusarczyk, et al.
European Journal of Medicinal Chemistry|May 1, 2016
Design and synthesis of novel bicalutamide and enzalutamide derivatives as antiproliferative agents for the treatment of prostate cancerMarcella Bassetto, Salvatore Ferla, Fabrizio Pertusati, et al.
Medchemcomm|August 16, 2018
Rational design and synthesis of novel phenylsulfonyl-benzamides as anti-prostate cancer agentsMarcella Bassetto, Salvatore Ferla, Gilda Giancotti, et al.
Biochemical Pharmacology|June 11, 2011
The cytostatic activity of NUC-3073, a phosphoramidate prodrug of 5-fluoro-2'-deoxyuridine, is independent of activation by thymidine kinase and insensitive to degradation by phosphorolytic enzymesJohan Vande Voorde, Sandra Liekens, Christopher McGuigan, et al.
European Journal of Medicinal Chemistry|July 10, 2019
A new series of bicalutamide, enzalutamide and enobosarm derivatives carrying pentafluorosulfanyl (SF<sub>5</sub>) and pentafluoroethyl (C<sub>2</sub>F<sub>5</sub>) substituents: Improved antiproliferative agents against prostate cancerFabrizio Pertusati, Salvatore Ferla, Marcella Bassetto, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
Bicyclic anti-VZV nucleosides: thieno analogues bearing an alkylphenyl side chain have reduced antiviral activityAnnette Angell, Christopher McGuigan, Luis Garcia Sevillano, et al.
Multiple Sclerosis and Related Disorders|September 10, 2021
Vaccine hesitancy among people with multiple sclerosisSiew Mei Yap, Mahmood Al Hinai, Maria Gaughan, et al.
Journal of Medicinal Chemistry|August 4, 2009
The application of phosphoramidate protide technology to acyclovir confers anti-HIV inhibitionMarco Derudas, Davide Carta, Andrea Brancale, et al.
Bioorganic & Medicinal Chemistry|June 24, 2011
Design, synthesis and biological evaluation of 2'-deoxy-2',2'-difluoro-5-halouridine phosphoramidate ProTidesMaurizio Quintiliani, Leentje Persoons, Nicola Solaroli, et al.
Pageof 16